Allogene Therapeutics - Public Comps and Valuation Multiples

Allogene Therapeutics Overview

About Allogene Therapeutics

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Founded

2017

HQ

Employees

229

Website

allogene.com

Sectors

Drug Development & Therapeutics
Vaccines & Immunotherapies
BioTech

Financials

LTM Revenue $9K

LTM EBITDA -$235M

EV

$56.8M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Allogene Therapeutics Financials

As of August 2025, Allogene Therapeutics reported last 12-month revenue of $9K and EBITDA of -$235M.

In the same period, Allogene Therapeutics achieved -$225M in LTM net income.

See Allogene Therapeutics valuation multiples based on analyst estimates

Allogene Therapeutics P&L

In the most recent fiscal year, Allogene Therapeutics reported revenue of $22K and EBITDA of -$243M.

Allogene Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Allogene Therapeutics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$9K	XXX	$22K	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	-$235M	XXX	-$243M	XXX	XXX	XXX
EBITDA Margin	-2588307%	XXX	-1106032%	XXX	XXX	XXX
EBIT	-$243M	XXX	-$257M	XXX	XXX	XXX
EBIT Margin	-2675062%	XXX	-1170373%	XXX	XXX	XXX
Net Profit	-$225M	XXX	-$258M	XXX	XXX	XXX
Net Margin	-2479692%	XXX	-1170864%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Allogene Therapeutics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $9K. EBITDA for the last twelve months was -$235M. In the most recent fiscal year, Allogene Therapeutics achieved $22K in revenue and -$243M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$9K	Analyst estimates available to subscribers	$22K	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	NaN% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$235M	Analyst estimates available to subscribers	-$243M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-2588307.5% EBITDA margin	Analyst estimates available to subscribers	-1106031.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$243M	Analyst estimates available to subscribers	-$257M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-2675062.2% EBIT margin	Analyst estimates available to subscribers	-1170372.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$225M	Analyst estimates available to subscribers	-$258M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-2479692.5% net profit margin	Analyst estimates available to subscribers	-1170863.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Allogene Therapeutics

This financial data table provides comprehensive performance metrics for Allogene Therapeutics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Allogene Therapeutics generated $9K in revenue over the last twelve months.
The company achieved -$235M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$225M.

Fiscal Year Performance

In the most recent fiscal year, Allogene Therapeutics reported $22K in total revenue.
Fiscal year EBITDA was -$243M.
The company maintained a gross profit margin of NaN% in the most recent fiscal year.
EBITDA margin for the fiscal year was -1106031.8%.
Net profit margin reached -1170863.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Allogene Therapeutics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Allogene Therapeutics Stock Performance

Allogene Therapeutics has current market cap of $251M, and EV of $56.8M.

Market Cap Evolution

Allogene Therapeutics Stock Data

As of September 12, 2025, Allogene Therapeutics's stock price is $1.

See Allogene Therapeutics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$56.8M	$251M	XXX	XXX	XXX	XXX	$-1.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Allogene Therapeutics Valuation Multiples

Allogene Therapeutics's trades at 2583.9x EV/Revenue multiple, and -0.2x EV/EBITDA.

See valuation multiples for Allogene Therapeutics and 15K+ public comps

Allogene Therapeutics Financial Valuation Multiples

As of September 12, 2025, Allogene Therapeutics has market cap of $251M and EV of $56.8M.

Equity research analysts estimate Allogene Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Allogene Therapeutics has a P/E ratio of -1.1x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$251M	XXX	$251M	XXX	XXX	XXX
EV (current)	$56.8M	XXX	$56.8M	XXX	XXX	XXX
EV/Revenue	6267.5x	XXX	2583.9x	XXX	XXX	XXX
EV/EBITDA	-0.2x	XXX	-0.2x	XXX	XXX	XXX
EV/EBIT	-0.2x	XXX	-0.2x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-1.1x	XXX	-1.0x	XXX	XXX	XXX
EV/FCF	-0.3x	XXX	-0.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Allogene Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Allogene Therapeutics Margins & Growth Rates

Allogene Therapeutics's last 12 month revenue growth is 28%

Allogene Therapeutics's revenue per employee in the last FY averaged $0K, while opex per employee averaged $1.1M for the same period.

Allogene Therapeutics's rule of 40 is -316070% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Allogene Therapeutics's rule of X is -2588237% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Allogene Therapeutics and other 15K+ public comps

Allogene Therapeutics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	28%	XXX	-17%	XXX	XXX	XXX
EBITDA Margin	-2588307%	XXX	-1106032%	XXX	XXX	XXX
EBITDA Growth	-3%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-316070%	XXX	-1106004%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-2588237%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0K	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	874086%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	1170473%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial